Metatrutide
Retatrutide analog
Metatrutide (Retatrutide analog) is a metabolic & fat loss research compound. Marketed as a triple GLP-1 / GIP / glucagon agonist in the retatrutide family. The peptide sequence sold under this name is not published and does not correspond to a compound in clinical development.
Metatrutide quick facts
| Reported research dose | 1mg-12mg weekly |
| Route | Subq |
| Frequency | 1x |
| Half-life | Unknown |
| Forms | Injectable |
| Evidence level | No published trial exists for this specific molecule |
Listed because it's being sold and people are asking. Be clear-eyed: retatrutide has real phase II data; 'metatrutide' does not. An unpublished sequence with no pharmacokinetics and no safety data is not a better retatrutide, it's an unknown. If the triple-agonist mechanism is the goal, retatrutide is the one with evidence behind it.
How Metatrutide works
Marketed as a triple GLP-1 / GIP / glucagon agonist in the retatrutide family. The peptide sequence sold under this name is not published and does not correspond to a compound in clinical development.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get Metatrutide
Buy Metatrutide at Disguised Alpha →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Metatrutide
Graded by what exists behind each claim.
✅ Clinically validated
- This name is used in the research-chemical market for a GLP-1 / GIP / glucagon triple agonist, referring to the mechanism of Eli Lilly's retatrutide. Retatrutide's phase 2 reported around 24% weight loss at 48 weeks — the largest figure any obesity drug has produced — and it is in phase 3.
- What is sold under this name is not the trial drug. The clinical data belongs to a specific molecule made under pharmaceutical manufacturing; a research-chemical vial with a similar name inherits none of it, and identity and purity are unverified.
📊 Correlative data
- Research-market use only. Reported experience mirrors the class — strong appetite suppression, GI effects, and a heart rate increase that shows up consistently and is the glucagon arm.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- Three receptors, three jobs: GLP-1 suppresses appetite and slows gastric emptying, GIP appears to improve tolerability and adipose insulin sensitivity, glucagon raises energy expenditure and drives hepatic fat oxidation.
- Adding expenditure to intake suppression is why the ceiling moves. Every single- and dual-agonist works mostly by reducing what goes in; the glucagon arm is the first mechanism in the class that increases what goes out.
- The predicted costs are equally mechanistic: higher heart rate, greater dependence on a correct receptor ratio, and — at 24% weight loss — real lean-mass loss without deliberate protein and resistance training.
What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Metatrutide actually does
Start with the search, because it is the finding. On 4 September 2026 a full-corpus search of NCBI PubTator3 for the string metatrutide returned count: 0. Not a trial, not a discovery paper, not a case report, not a letter. Zero indexed documents of any kind. The same corpus holds retatrutide’s phase 2 in the New England Journal of Medicine Jastreboff 2023, its phase 2a liver trial in Nature Medicine Sanyal 2024, and a phase 3 in the Lancet Bajaj 2026.
So this section cannot be about what this molecule does, because no published experiment has ever been performed on it. It has to be about the mechanism the name points at, and about the specific things a name does not carry across.
The mechanism, which is real and belongs to retatrutide. Three receptors, three jobs, and they are not additive in the way the marketing implies.
GLP-1 receptor. Appetite suppression, glucose-dependent insulin secretion, delayed gastric emptying. This is the arm that produces the nausea and the arm every compound in this category has.
GIP receptor. The genuinely unsettled one. GIP receptor agonism and GIP receptor antagonism have both been developed into weight-loss drugs, which is an unusual state of affairs for a target and is flagged as an open question in the field’s own review of anti-obesity drug discovery Muller 2022. Nobody selling a triple agonist mentions that the direction of the middle arm is contested.
Glucagon receptor. The liver arm. It raises energy expenditure and drives hepatic fat oxidation, and that is where the extra weight loss above a GLP-1 comes from. It also raises hepatic glucose output and it raises heart rate. Every benefit and every risk attributed to ‘the triple’ over ‘the single’ traces back to this receptor.
The ratio is the drug, and for this compound there is no ratio and no drug to have one. For a multi-agonist the potency ratio across the three receptors decides everything: how much heart rate you buy per kilogram lost, whether fasting glucose rises or falls, whether the fat comes off the liver or off the hip. Worth stating plainly: the three registered-trial publications for retatrutide describe it as an agonist of the GIP, GLP-1 and glucagon receptors and none of the three prints a potency ratio Jastreboff 2023 Sanyal 2024 Bajaj 2026. So the number that defines the class is missing even for the molecule that has trials. For the molecule that does not, the question is not what the ratio is — it is whether all three arms are present at all.
And here is the part that makes this compound different from every other unverified peptide on this site. Three receptors means three independent ways to be wrong, and two of the three failures are invisible to the person taking it. A peptide that has lost its glucagon arm, or never had one, still activates GLP-1, still suppresses appetite, still causes nausea and still produces weight loss. It just produces a GLP-1’s weight loss rather than a triple’s. The subjective experience of a working triple agonist and of a plain semaglutide-grade GLP-1 are the same experience. There is no sensation that reports receptor coverage.
Cell, rodent, human — and where it stops
Step one, in cells: nothing. No published receptor-activation assay, no cAMP EC50, no binding constant has ever been reported for anything sold under this name.
Step two, in rodents: nothing. No published animal study.
Step three, in humans: nothing. No trial, no case series, no pharmacokinetic sampling, no adverse-event report in the indexed literature.
That is the entire translation chain for this compound, and writing it out is more useful than pretending it is short. What follows is the chain belonging to retatrutide, the molecule the name gestures at, stated so the size of the gap is visible.
Retatrutide, phase 2, 48 weeks (NCT04881760). Least-squares mean weight change was −8.7% at 1 mg, −17.1% in the combined 4 mg group, −22.8% in the combined 8 mg group and −24.2% at 12 mg, against −2.1% on placebo Jastreboff 2023. That 24.2% is the largest figure any obesity drug has produced in a randomized trial, and it is the number the research-chemical market is selling. The same paper reports dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter — hold that, it becomes the only home test on this page.
Retatrutide, phase 2a in liver disease, same registration. 98 participants randomized to 48 weeks of once-weekly subcutaneous retatrutide at 1, 4, 8 or 12 mg or placebo. Mean relative change in liver fat at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg) and −82.4% (12 mg) against +0.3% on placebo, all p < 0.001 Sanyal 2024. Put that next to the best dual-agonist liver number in this same catalog: pemvidutide reduced liver fat 68.5% at 1.8 mg over 12 weeks Harrison 2024. The third receptor is doing something real, and the liver is where it shows.
Retatrutide, phase 3. TRANSCEND-T2D-1, a double-blind randomized phase 3 in people with type 2 diabetes inadequately controlled with diet and exercise Bajaj 2026. The program is a real one, run to a regulatory standard.
The obstacle, and it is not the usual one. Normally the obstacle in this section is a species gap or a route gap. Here the obstacle is that every number above was generated with material made by a pharmaceutical manufacturer to a filed specification, and five things about that material are unverifiable in a research-market vial: (1) the amino acid sequence; (2) the position and chemistry of the fatty-acid acylation, which is what makes it weekly rather than hourly; (3) the impurity profile, including deletion sequences that differ from the target by one residue; (4) the aggregation state, since acylated peptides self-associate and an aggregated peptide has different kinetics; (5) endotoxin. None of the five produces a symptom that identifies it.
One concrete tell that the borrowing has already happened. This site’s own card lists the dose as 1 mg to 12 mg weekly. That is not a dose anybody titrated for this material. It is exactly the dose ladder of retatrutide’s phase 2 arms — 1, 4, 8 and 12 mg Jastreboff 2023. The dosing instruction on every vendor page for this compound is a trial protocol for a different molecule, transcribed.
Metatrutide pharmacokinetics — how much of it actually gets in
The catalog says ‘Unknown’. That is the correct word, and it is also where every other page about this compound stops. The arithmetic underneath it is more useful than the blank.
The measured record: zero. There are 0 published pharmacokinetic measurements of anything sold as metatrutide, in any species, by any route. No Cmax, no AUC, no terminal half-life, no accumulation ratio.
What degrades it, assuming the vial contains what it claims. A weekly incretin peptide survives by binding albumin through a fatty diacid side chain: the albumin-bound fraction is too large for glomerular filtration and is shielded from circulating peptidases, and the free fraction is topped up continuously from that reservoir Muller 2022. Once free, it is subject to proteolysis by plasma and tissue peptidases and to renal handling; the native GLP-1 backbone is also cut by dipeptidyl peptidase-4 at the second residue unless that position has been substituted, which every long-acting analog in this class does one way or another — ecnoglutide, for instance, carries an alanine-to-valine change at position 8 for exactly this reason Guo 2023. None of these molecules is a cytochrome substrate, which is why the class does not carry the drug-interaction lists small molecules do.
The number that bounds it, borrowed honestly. The only measured half-life in this entire cohort belongs to ecnoglutide: 124 to 138 hours at steady state, which is 5.2 to 5.8 days, and that is what supports its once-weekly schedule Guo 2023. Any properly acylated weekly incretin sits in that neighborhood. So the arithmetic runs: if the vial holds a correctly acylated triple agonist, a weekly injection maintains roughly 60–70% of peak exposure at day 7 and accumulates over 4 to 5 doses to steady state. If the acylation is absent or in the wrong place, the same peptide is cleared in minutes to hours, and a weekly schedule delivers one to two days of drug followed by five days of nothing.
Those two cases are not indistinguishable, and that matters. They are indistinguishable in a vial and distinguishable in a person. An unacylated peptide dosed weekly produces appetite suppression that arrives within hours and is gone by day 2 or 3, with hunger returning hard before the next injection. A correctly acylated one produces flat appetite suppression across the whole week. Anyone running this compound already has the data to tell which vial they bought, and almost nobody records it.
The oral barrier. Absolute. Swallowed, an acylated 39-residue peptide meets gastric acid, then pancreatic proteases, then brush-border peptidases, and anything intact still faces hepatic first-pass extraction. No oral bioavailability figure exists for this compound and none is possible without a permeation enhancer co-formulated at pharmaceutical scale.
The injectable comparator, which is the only route in use. Subcutaneous injection, once weekly, 29–31 gauge. Subcutaneous dosing removes the gut and the first-pass liver; it does not remove plasma peptidases, and it does not answer whether the molecule in the syringe is the molecule on the label.
What would have to be true, and how you would know it was not
Four predictions. The first is the important one, it costs nothing, and it argues against the product rather than for it.
1. Resting heart rate should rise — and if it does not, the vial probably has no glucagon arm. Retatrutide produced dose-dependent heart-rate increases that peaked at 24 weeks and then declined Jastreboff 2023, and heart rate is a consistent, measured, class-level consequence of incretin agonism across meta-analysis Yang 2023. Take a seated resting pulse every morning before caffeine for a week before starting, then weekly. The prediction for genuine triple material is a rise of several beats per minute that builds over months. The falsification is a person losing 15% of their body weight with a completely flat resting pulse, which is the signature of a GLP-1-only molecule sold under a triple-agonist name. That single observation is worth more than any certificate of analysis a vendor supplies, because it is a measurement of the pharmacology rather than a claim about the powder.
2. Fasting glucose and HbA1c, watched for the wrong direction. Glucagon raises hepatic glucose output; GLP-1 suppresses it. In a balanced triple the GLP-1 arm wins and glycemia improves, which is what the phase 3 diabetes program is testing Bajaj 2026. Draw HbA1c and fasting insulin at baseline, 12 weeks and 24 weeks. Falling weight with rising fasting glucose is the specific signature of a glucagon arm that is over-weighted relative to the GLP-1 arm — a ratio problem, and the one lab pattern that would tell you the ratio is wrong without ever measuring a receptor.
3. Liver enzymes should fall, and the CMP is where you see it. Retatrutide cut liver fat by more than 80% at the top two doses Sanyal 2024. Hepatic fat and ALT track each other loosely but reliably enough at that effect size, and ALT sits on a standard CMP. Baseline and 24 weeks. An ALT that does not move at all in somebody who started with a fatty liver and lost 15% of their weight is evidence against the third receptor being engaged.
4. Lean mass will not be spared, and nothing about a third receptor changes that. Across weight-loss pharmacotherapy, more than 25% of total weight lost comes from fat-free mass Stefanakis 2024. At retatrutide’s −24.2% Jastreboff 2023, that is roughly 6% of starting body weight as fat-free mass. Measure grip strength at baseline, 12 and 24 weeks. Grip strength falling while weight falls is the failure mode, and it is the one no vendor page mentions.
What nobody has tested yet
Four experiments, and the first two could be done by the people already buying this.
1. Nobody has run a mass spectrum on a vial sold as metatrutide. Not one published analysis of the research-market material exists — no molecular weight, no sequence confirmation, no purity figure, no acylation check. Three lots from three vendors and one liquid-chromatography tandem mass spectrometry run would generate the first compositional data this compound has ever had, and it would answer the question the whole page turns on: is it a triple agonist, a dual, a GLP-1, or a peptide of a different sequence entirely.
2. Nobody has collected paired heart rate and weight from users of this compound. Both are free, both are daily, and together they are a functional receptor assay run in a bathroom: weight loss reports the GLP-1 arm, resting pulse reports the glucagon arm Jastreboff 2023 Yang 2023. Fifty people logging both for 24 weeks would produce more information about what is actually in this market than anything currently published.
3. Whether the GIP arm contributes anything to the human result. The field has not settled whether GIP receptor agonism or antagonism is the useful direction Muller 2022, and no trial has ever compared a GLP-1/glucagon dual against a GIP/GLP-1/glucagon triple at matched GLP-1 and glucagon exposure. Until that arm is run, the third receptor's contribution to the extra weight loss is an assumption, not a measurement.
4. Whether the liver-fat effect survives weight-matching. Retatrutide cut liver fat 82% Sanyal 2024 while cutting body weight 24% Jastreboff 2023. Nobody has run a triple agonist against a diet arm matched for weight loss, so it is still unknown how much of that liver-fat reduction is glucagon-driven hepatic fat oxidation and how much is simply what happens to a liver when a person loses a quarter of their body mass. That is the single most interesting unrun experiment in this whole drug class.
Metatrutide — its own safety story, not its class's
The class safety block on this page describes GLP-1 receptor agonist risk. That block is about drugs whose identity is known. Here the dominant risk is upstream of pharmacology entirely, so it goes first.
1. Identity risk, which is this compound’s actual risk profile. With zero indexed publications, zero pharmacokinetics and zero analytical characterization of the marketed material, the honest statement is that nobody knows what is in the vial, including the person selling it. The specific hazards of an uncharacterized acylated peptide are not exotic: deletion-sequence impurities that differ by one residue and carry unknown pharmacology; aggregation, which changes both kinetics and immunogenicity; and endotoxin, which produces fever and rigors within hours of injection and is the one identity failure that announces itself.
2. Heart rate is the mechanism-specific risk and it is not trivial. Retatrutide’s heart-rate rise was dose-dependent and peaked at 24 weeks Jastreboff 2023; the class effect is measured across meta-analysis Yang 2023. A sustained resting-pulse elevation is tolerated in a monitored trial population screened for cardiac disease. It is a different proposition in an unscreened person self-dosing an unquantified amount of an unidentified peptide.
3. The glucagon arm and glucose, which runs opposite to what buyers expect. People take these compounds expecting glucose to improve. A glucagon receptor agonist, unopposed, raises hepatic glucose output. In anyone already taking insulin or a sulfonylurea the interaction runs both ways and is unpredictable when the ratio of the two arms is unknown — which here it is.
4. Gallbladder disease, a real class effect with a specific size attached. Across 76 randomized trials and 103,371 patients, GLP-1 receptor agonist use carried a relative risk of gallbladder or biliary disease of 1.37 (95% CI 1.23–1.52), and the signal was far larger in weight-loss trials (2.29, 1.64–3.18) than in diabetes trials (1.27), with higher risk at higher doses He 2022. Anyone using this for weight loss is in the 2.29 stratum. Right upper quadrant pain after meals is the symptom, and it is not a gastrointestinal side effect to titrate through.
5. What the pooled human data does and does not exonerate. Across 60,080 patients in GLP-1 outcome trials there was no pancreatic cancer signal Sattar 2021. That is genuine reassurance about the mechanism. It is not reassurance about this vial, because the 60,080 patients received characterized drug.
What zero means. There are 0 published adverse events for metatrutide, because there has never been a study in which one could have been recorded. An empty safety record and a clean safety record look identical on a product page and are opposites.
Sources read for this page
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine 2023 · PMID 37366315
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine 2024 · PMID 38858523
- Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet 2026 · PMID 42250575
- Harrison SA, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology 2024 · PMID 39002641
- Guo W, et al. Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Molecular Metabolism 2023 · PMID 37364710
- Yang Y, et al. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis. Diabetes, Obesity and Metabolism 2023 · PMID 37860884
- He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
- Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534
- Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology 2021 · PMID 34425083
- Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532
Metatrutide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Metatrutide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Metatrutide moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Metatrutide in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Metatrutide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
Metatrutide — frequently asked questions
What is Metatrutide?
Metatrutide (Retatrutide analog) is a metabolic & fat loss research compound. Marketed as a triple GLP-1 / GIP / glucagon agonist in the retatrutide family. The peptide sequence sold under this name is not published and does not correspond to a compound in clinical development.
Is the full Metatrutide protocol on this page?
The reported research dose is on this page, along with how Metatrutide works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Metatrutide?
Metatrutide has an approximate half-life of Unknown, which is part of what determines how often it's dosed.
What's the evidence behind Metatrutide?
Current evidence level: No published trial exists for this specific molecule. Metatrutide is offered for research purposes only and is not an approved medicine.
What Metatrutide is used for
Metatrutide appears under 1 goal in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.